Evidence for low-density lipoprotein–induced expression of connective tissue growth factor in mesangial cells  by Sohn, Mimi et al.
Kidney International, Vol. 67 (2005), pp. 1286–1296
Evidence for low-density lipoprotein–induced expression of
connective tissue growth factor in mesangial cells
MIMI SOHN, YAN TAN, RICHARD L. KLEIN, and AYAD A. JAFFA
Department of Medicine, Endocrinology-Diabetes-Medical Genetics, Medical University of South Carolina, Charleston,
South Carolina; and The Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina
Evidence for low-density lipoprotein–induced expression of
connective tissue growth factor in mesangial cells.
Background. Although hyperlipidemia is a risk factor for
the progression of renal damage, the relationship between in-
creased plasma lipoproteins and glomerular injury is poorly
defined. Connective tissue growth factor (CTGF) is emerging
as a key determinant of progressive fibrotic diseases and its
expression is up-regulated by diabetes. To define the mecha-
nisms through which low-density lipoproteins (LDLs) promote
glomerular injury, we evaluated whether LDL can modulate the
expression of CTGF and collagen I.
Methods. The effects of LDL on CTGF and collagen I ex-
pression were carried out in rat mesangial cells.
Results. Treatment of mesangial cells with LDL for 24 hours
produced a significant increase in the protein levels of CTGF
and collagen I compared to unstimulated controls. To explore
if CTGF and collagen I are downstream targets for regulation
by transforming growth factor-b (TGF-b), mesangial cells were
treated with various concentration of TGF-b for 24 hours. TGF-
b produced a concentration-dependent increase in the protein
levels of CTGF and collagen I. The increase in CTGF and col-
lagen I induced by LDL was significantly inhibited by neutraliz-
ing anti-TGF-b antibodies. Inhibition of p38mapk or p42/44mapk
activities did not affect LDL-induced TGF-b1, CTGF, and col-
lagen I expression, whereas inhibition of c-Jun NH2-terminal
kinase (JNK) suppressed LDL-induced TGF-b , CTGF, and col-
lagen I expression.
Conclusion. These findings implicate JNK pathway and TGF-
b1 as key players in LDL signaling leading to CTGF and col-
lagen I expression in mesangial cells. The data also point to a
potential mechanistic pathway through which lipoproteins may
promote glomerular injury.
Diabetic nephropathy is the leading cause of end-stage
renal failure, and is clinically manifested by albuminuria,
hypertension, and a progressive decline in glomerular fil-
tration rate (GFR) [1–3]. About 30% to 40% of patients
with type 1 diabetes develop progressive nephropathy
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[3]. A very characteristic and initial event of the devel-
opment of diabetic nephropathy is glomerulosclerosis,
which is featured by increased thickness of the glomeru-
lar basement membrane (GBM), and a widening of the
mesangium with accumulation of extracellular matrix
(ECM). The development of glomerulosclerosis is clearly
dependent on hyperglycemia since intensive control of
glycemia in type 1 diabetic patients was associated with a
reduction of glomerular lesions [4]. Although the associ-
ation of chronic hyperglycemia and diabetic nephropathy
is well established, the risk factors and cellular signaling
mechanisms that promote glomerulosclerosis in diabetes
are still undefined. In this regard, the cytokine transform-
ing growth factor-b (TGF-b) has been shown to play a
pivotal role in mesangial cell expansion and matrix depo-
sition [5]. Recent evidence indicates that the profibrotic
signals initiated by TGF-b are mediated via activation of
connective tissue growth factor (CTGF) [6].
CTGF was originally identified as a product of human
umbilical vein endothelial cells that was both chemotatic
and mitogenic for fibroblasts [7]. It is now known that
CTGF belongs to a new gene family, CCN (named
after prototype members of this family CTGF, cyr61,
and nov) [8]. The molecular weight of CTGF-like fac-
tors varies between 35 and 40 kD, and the structure of
these molecules consists of four modules: an N-terminal
insulin-like growth factor binding protein (IGFBP)-like
domain, a von Willebrand factor type C repeat domain, a
thrombospondin type 1 repeat domain, and a C-terminal
dimerization domain [8].
The biologic actions of CTGF are pleiotropic and seem
to be cell specific, but the cellular mechanisms of its ac-
tions are still undefined. An emerging role of CTGF is
that of a prosclerotic factor. Renal expression of CTGF
is up-regulated by the diabetic state and by other pro-
gressive renal diseases [9]. In addition, CTGF has been
shown to increase collagen I expression in human mesan-
gial cells [10].
Poorly controlled type 1 diabetes is usually associated
with elevated levels of plasma LDL, intermediate-density
lipoproteins and very low-density lipoprotein levels
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[11–14]. Besides quantitative abnormalities, patients with
type 1 diabetes are known to have significant quali-
tative lipoprotein abnormalities. Abnormalities in lipid
and lipoprotein metabolism are commonly associated
with end-stage renal disease (ESRD) [15–17]. Specifi-
cally, hyperlipidemia and the glomerular deposition of
atherogenic lipoproteins (LDL and oxidized LDL) are
implicated in key pathologic processes involved in the de-
velopment of glomerular disease, including stimulation of
monocyte infiltration into the mesangial space, mesangial
cell hypercellularity, and ECM deposition [17, 18].
Although hyperlipidemia is now considered a risk fac-
tor for the progression of renal damage, the relationship
between increased plasma lipoproteins and glomerular
injury is poorly defined. Hyperlipidemia can directly or
indirectly stimulate the synthesis and release of factors
from resident renal cells which in turn can stimulate
mesangial cell growth, as well as ECM production in an
autocrine or paracrine manner [19, 20]. Therefore, the
present study was designed to explore the potential role
of LDL in modulating the expression of CTGF in mesan-
gial cells and to delineate the cellular signaling mecha-
nisms through which this regulation may occur.
METHODS
Mesangial cell culture
Rat glomerular mesangial cells were prepared by a
modification of the method of Lovett et al [21]. Glomeru-
lar cells collected as described above were incubated in
phosphate-buffered saline (PBS) plus 0.1% gentamysin
solution and 1% antibiotic antimycotic, pH 7.4, contain-
ing collagenase (5mg/mL), at 37◦C for half an hour to
remove epithelial cells, leaving the glomerular cores con-
taining mesangial and endothelial cells, vortexed every
10 minutes during the incubation. The cores were di-
luted in 1.5 mL RPMI 1640 medium with Hepes and L-
glutamine (Invitrogen Corporation, Carlsbad, CA, USA)
per kidney, containing 0.1% gentamycin solution, 1%
antibiotic antimycotic, 0.5% insulin transferring solu-
tion, and 20% fetal bovine serum (FBS), conditions
which favor growth of mesangial cells. Cells were in-
cubated at 37◦C in a humidified atmosphere of 95%
air/5%CO2. Cell viability was assessed by standard dye
exclusion techniques, using 0.1% Trypan blue. Mesangial
cells were identified by the following criteria. Mesangial
cells stained positive for intracellular cytoskeletal fibrils
of actin and smooth muscle cell (SMC)-specific myosin
(indicative of contractile cells), desmin, and vimentin and
negative for cytokeratin and factor VIII antigens. Mor-
phologically, mesangial cell had an elongated and stellate
or spindle-shaped morphology. Mesangial cells isolated
by this procedure were homogenous and used in all stud-
ies between passages 3 and 8.
LDL preparation and characterization
LDL was prepared as previously described [22]. Briefly,
blood was taken from fasting healthy nondiabetic vol-
unteers into a lipoprotein preservative/antioxidant cock-
tail (LPPC) containing ethylenediaminetetraacetic acid
(EDTA) (0.1% wt/vol), chloramphenicol (20 lg/mL),
gentamycin sulfate (50 lg/mL), and e-amino-n-caproic
acid (0.13%, wt/vol). Phenylmethylsulfonyl fluoride
(PMSF), 20lg/mL final concentration, was added to
plasma to retard proteolysis. All samples were processed
at low temperature and in the absence of white light
to minimize oxidation. All density solutions were sup-
plemented with LPPC, degassed, and purged with N2.
Plasma density was increased to d = 1.21 g/mL using
dried KBr and 11 mL layered under d = 1.019 g/mL
saline/LPPC. After ultracentrifugation (Beckman VTi50
rotor), 2 12 hours 50,000 rpm 7
◦C with slow acceleration
and deceleration, the LDL band was harvested by pierc-
ing the tube and aspirating into a syringe. LDL iso-
lated by this procedure was free from contamination with
apolipoprotein A (ApoA-I) and albumin.
Each LDL preparation was characterized for purity
by electrophoresis on 1% agarose gels (Paragon gels)
(Beckman, Brea, CA, USA). The LDL pools were tested
for endotoxin contamination by the Limulus Amebocyte
Lysate (BioWhittaker, Walkersville, MD, USA) accord-
ing to the manufacturer’s suggestion.
Cell extracts
Mesangial cells treated with LDL were washed twice
in ice-cold PBS, scraped in PBS containing 2 mmol/L
sodium vanadate, and centrifuged at 3000g for 5 min-
utes. Pellets were resuspended in 100 mL of lysis buffer
(20 mmol/L Tris, 130 mmol/L NaCl, 10% glycerol,
10 mmol/L CHAPS, 1 mmol/L PMSF, 2 mmol/L sodium
vanadate, 100 mU/mL aprotinin, and 0.156 mg/mL ben-
zamidin, pH 8.0), incubated on ice for 30 minutes and
centrifuged at maximum speed for 5 minutes. The super-
natant was used as the protein source and its concentra-
tion was determined by a BCA Protein Assay Kit (Pierce,
Rockford, IL, USA) using bovine serum albumin (BSA)
as a standard protein.
Western blotting of CTGF and collagen I
Mesangial cells were cultured in 6-well plates (9.6 cm2/
well). At 80% confluence, cells were serum starved by
the changing of serum-free media (RPMI medium1640
with 25 mmol/L Hepes buffer, 11.11 mmol/L glucose,
and L-glutamine) within 24 hours. Quiescent mesangial
cells were stimulated with LDL (50 lg/mL) for 24 hours
in the presence and absence of either a p42/p44mapk in-
hibitor (PD98059), 40lmol/L (Calbiochem, La Jolla, CA,
USA), a p38mapk inhibitor (SB203580), 10 lmol/L (Cal-
biochem), and/or the c-Jun NH2-terminal kinase (JNK)
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inhibitor (SP600125), 30 lmol/L (A.G. Scientific, San
Diego, CA, USA). Soluble protein (20 to 25 lg) obtained
as described above was separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
(12% CTGF and 7.5% collagen I), under reducing con-
ditions and transferred onto nitrocellulose membrane
(Bio-Rad, Hercules, CA, USA) with semitransfer method
(Bio-Rad) at 20 volts for 50 minutes. The membranes
were immunoblotted with anti-CTGF polyclonal anti-
body (1:1000 dilution), anticollagen I polyclonal antibody
(1:1000 dilution) (Southern Biothechnology, Birming-
ham, AL, USA), and antiactin antibody (1:1000 dilution)
(Sigma Chemical Co., St. Louis, MO, USA) overnight
at 4◦C followed by incubating the membranes in a sec-
ondary antibody conjugated to horseradish peroxidase
(HRP). The immunoreactive bands were visualized using
the chemiluminiscence reagent Renaissance (NEN Life
Science Products, Boston, MA, USA), according to the
procedure described by the supplier. Membranes were
exposed to Kodak LS film and bands were measured
by densitometry and quantified by Scion Image program
(Scion Corporation, Frederick, MA, USA).
Mitogen-activated protein kinase (MAPK) assays
Quiescent mesangial cells stimulated with LDL (50 lg/
mL) for 5 minutes. Twenty-five to thirty micrograms
of protein was analyzed by SDS-PAGE and the sepa-
rated proteins were transferred to nitrocellulose mem-
brane with semitransfer method and immunoblotted
with antiphospho-p42/p44mapk polyclonal antibody that
detects p42 and p44 MAPK only when activated by
phosphorylation at Thr202 and Tyr204 (1:4000 dilu-
tion) (Cell Signaling Technology, Inc., Beverly, MA,
USA), antiphospho-p38mapk antibody that detects p38
only when activated by phosphorylation at Thr180 and
Tyr182 (1:1000 dilution) (Cell Signaling Technology, Inc.)
and anti-JNK antibody that detects JNK only when acti-
vated by phosphorylation at Thr183 and Tyr185 (1:1000
dilution) (Cell Signaling Technology, Inc.). Immunore-
active bands were visualized using the chemiluminis-
cence reagent Renaissance, according to the procedure
described by the supplier. Membranes were exposed to
Kodak LS film and bands were measured by densitometry
and quantified by Scion Image program.
TGF-b1 protein level determination
Mesangial cells were cultured in 6-well plates (9.6 cm2/
well). At 80% confluence, cells were serum starved
by the changing of serum-free media within 24 hours.
Cells were then stimulated for 24 hours with LDL
(50 lg/mL), in presence or absence of the p42/p44mapk
inhibitor (PD98059), 40 lmol/L, the p38mapk inhibitor
(SB203580), 10 lmol/L, and/or the JNK inhibitor
(SP600125), 30 lmol/L, in exactly 1.5 mL of medium.
TGF-b1 protein levels were determined by colorimet-
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Fig. 1. Low-density lipoprotein (LDL) stimulates the regulation of col-
lagen I protein in mesangial cells. Quiescent mesangial cells were stimu-
lated with 50 lg/mL of LDL for 24 hours. Cell proteins were separated
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and immunoblotted with antibodies against collagen I (1:1000)
and actin (1:1000). Bar graph represents intensities of collagen I bands
relative to actin and expressed as percent above control. Blots shown
are representative of 22 experiments. ∗P < 0.0005 vs. control.
ric enzyme-linked immunosorbent assay kit (ELISA)
(R& D System, Minneapolis, MN, USA) in the condi-
tioned media that were activated by 1 N HCl (to measure
both active and latent TGF-b1) according to the man-
ufacturer’s instructions, and expressed as picograms per
milliliter.
Statistical analysis
Data is expressed as mean ± SE and analyzed by Stu-
dent t test for unpaired analysis. Differences were con-
sidered significant if P < 0.05.
RESULTS
Induction of collagen I by LDL
To investigate whether LDL induces matrix formation,
we measured collagen I expression. Type I collagen is not
usually expressed under normal physiologic conditions
in mesangial cells, but can be induced in response to in-
jury or to growth factors. Mesangial cells were stimulated
with LDL (50 lg/mL) for 24 hours, and the protein lev-
els of collagen I were measured by Western blots. The
results shown in Figure 1 demonstrate that LDL stimula-
tion resulted in a significant increase in the production of
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Fig. 2. Low-density lipoprotein (LDL) stimulates the regulation of
connective tissue growth factor (CTGF) in mesangial cells. Quiescent
mesangial cells were stimulated with 50 lg/mL of LDL for 24 hours. Cell
proteins were separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) (12%) and immunoblotted with an anti-
body against CTGF (1:1000) and actin (1:1000). Bar graph represents
intensities of CTGF bands relative to actin expressed as percentage
above control. Blots shown are representative of 23 experiments. ∗P <
0.0001 vs. control.
collagen I compared to unstimulated cells (2346 ± 289 vs.
1589 ± 232 densitometric units; LDL vs. control, respec-
tively) (P < 0.0005) (N = 22). The levels of the structural
protein actin protein levels measured in the same cell ex-
tracts as control were not different between control and
LDL-treated cells.
Induction of CTGF by LDL
To begin to understand the cellular mechanisms
through which LDL promotes renal injury, we evaluated
whether LDL can modulate the expression of CTGF in
renal cells prone to injury. Mesangial cells were stimu-
lated with LDL (50 lg/mL) for 24 hours. The expression
of CTGF was measured by Western blots using specific
anti-CTGF antibodies. Figure 2 represents the intensities
of the CTGF bands expressed as percent increase above
control. The results indicate that LDL produced a signif-
icant increase in the expression of CTGF (1384 ± 144 vs.
897 ± 129 densitometric units; LDL vs. control, respec-
tively) (P < 0.0001) (N = 23). The levels of the structural
protein actin were also measured in the same cell ex-
tracts as control, to ensure equal loading of the samples
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Fig. 3. Induction of transforming growth factor-b1 (TGF-b1) protein
secretion by low-density lipoprotein (LDL) in mesangial cells. Quies-
cent mesangial cells were stimulated by LDL (50 lg/mL) for 24 hours.
Conditioned media were collected and activated to determine the total
level of TGF-b1 protein, using colorimetric enzyme-linked immunosor-
bent assay (ELISA) kit assay. Values are means ± SE of TGF-b1 levels
expressed in pg/mL (N = 26). ∗P < 0.0001 vs. control.
into the gel, and were not different between control and
LDL-treated cells.
This finding provides the first evidence that LDL can
directly modulate the expression of CTGF in mesangial
cells.
LDL stimulates TGF-b production in mesangial cells
We next assessed whether LDL will stimulate the pro-
duction of TGF-b protein levels. Mesangial cells were
treated with LDL (50 lg/mL) for 24 hours, and TGF-b
protein levels were measured in the conditioned media by
ELISA. The results shown in Figure 3 demonstrate that
LDL treatment resulted in a significant increase in the
production of TGF-b levels compared to unstimulated
cells (111.8 ± 14.2 pg/mL vs. 63.2 ± 9.7 pg/mL; LDL vs.
control, respectively) (P < 0.0001) (N = 26).
Induction of CTGF and collagen I by TGF-b
To explore the cellular mechanisms through which
LDL regulates the expression of CTGF and collagen I
in mesangial cells, we determined first if CTGF and col-
lagen I are downstream targets for regulation by TGF-b .
Mesangial cells were treated with various concentration
of TGF-b (0, 0.2, 0.5, 1, 5, and 10 ng/mL) for 24 hours. The
protein levels of CTGF and collagen I were measured by
Western blots. The levels of the structural protein actin
were also measured in the same cell extracts as control, to
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Fig. 4. Induction of connective tissue growth
factor (CTGF) and collagen I by transform-
ing growth factor-b (TGF-b). Mesangial cells
were treated with various concentration of
TGF-b 1 (0, 0.2, 0.5, 1, 5, and 10 ng/mL) for
24 hours. (A) Cell proteins were separated
by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) (12%) and im-
munoblotted with an antibody against CTGF
(1:1000) and actin (1:1000). Bar graph repre-
sents intensities of CTGF bands relative to
actin expressed as percentage above control.
Blots shown are representative of five sepa-
rate experiments. ∗P < 0.05 vs. control. (B)
Cell proteins were separate by SDS-PAGE
(7.5%) and immunoblotted with an antibody
against collagen I (1:1000) and actin (1:1000).
Bar graph represents intensities of collagen I
bands relative to actin expressed as percent-
age above control. Blots shown are represen-
tative of three separate experiments. ∗P < 0.05
vs. control.
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Fig. 5. Low-density lipoprotein (LDL) in-
duces connective tissue growth factor (CTGF)
and collagen I expression via autocrine acti-
vation of transforming growth factor-b (TGF-
b). Mesangial cells were stimulated with
50 lg/mL of LDL or 5 ng/mL of TGF-
b1 for 24 hours in presence or absence
of 5 lg/mL of neutralizing anti-TGF-b an-
tibody (TGF-b NA). (A) Equal amounts
of proteins were resolved on sodium dode-
cyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE) (12%) and immunoblotted
with an antibody against CTGF (1:1000) and
actin (1:1000). Bar graph represents intensi-
ties of CTGF bands relative to actin expressed
as percentage above control. Blots shown are
representative of nine experiments. ∗P < 0.01
vs. control; †P < 0.05 vs. LDL; ††P < 0.05
vs. TGF-b1. (B) Equal amounts of proteins
were resolved on SDS-PAGE (7.5%) and im-
munoblotted with an antibody against colla-
gen I (1:1000) and actin (1:1000). Bar graph
represent intensities of collagen I bands rela-
tive to actin expressed as percentage above
control. Blots shown are representative of
eight experiments. ∗P < 0.05 vs. control; †P
< 0.05 vs. LDL; ††P < 0.01 vs. TGF-b1.
ensure equal loading of the samples into the gel. The re-
sults shown in Figure 4 demonstrate that TGF-b resulted
in a concentration-dependent increase in the expression
of CTGF (P < 0.05) (N = 5) and collagen I (P < 0.05)
(N = 3) in mesangial cells. Actin protein levels were not
different between control and TGF-b–treated cells.
These findings indicate that TGF-b is upstream of
CTGF and collagen I and could play a key role in modu-
lating the expression of the prosclerotic cytokine CTGF
and of matrix protein collagen I.
Role of TGF-b in LDL-induced CTGF and collagen I
expression
To assess whether the induction of CTGF and collagen
I we observed in response to LDL is mediated via au-
tocrine activation of TGF-b , mesangial cells were treated
with LDL (50 lg/mL) for 24 hours in the presence and
absence of neutralizing anti-TGF-b (TGF-b NA) anti-
bodies (5 lg/mL) (R&D System), a concentration shown
to neutralize TGF-b action [23]. As a positive control,
mesangial cells were also treated with TGF-b (5 ng/mL)
for 24 hours in the presence and absence of neutraliz-
ing anti-TGF-b antibodies. The protein levels of CTGF,
collagen I, and actin were measured by Western blots.
The results shown in Figure 5 demonstrate that both
LDL and TGF-b produced a significant increase in CTGF
and collagen I production (P < 0.01 vs. control) (N = 9).
This increase in CTGF and collagen I in response to LDL
or TGF-b was significantly inhibited by the anti-TGF-b
NA (P < 0.05 vs. LDL and vs. TGF-b). These findings
are the first to implicate TGF-b as a key player in LDL
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Fig. 6. Phosphorylation of mitogen-activated protein kinase (MAPK) pathway by low-density lipoprotein (LDL). Quiescent mesangial cells were
stimulated with 50 lg/mL of LDL for 5 minutes. Cell proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) (12%) and immunoblotted with a polyclonal antibody against phospho-p44/42 (1:4000) and total-p44/42 (1:4000) (A), phospho-p38 (1:1000)
and total-p38 (1:4000) (B), and phospho-c-Jun NH2-terminal kinase (JNK) (1:1000) and total-JNK (1:4000) (C). Blots shown are representative of
12 experiments. Bar graph represents intensities of phospho-MAPK relative to total-MAPK expressed as percent phosphorylation above control.
Bars represent means ± SE of 12 experiments. ∗P < 0.0001 vs. control.
signaling leading to CTGF and collagen I expression in
mesangial cells.
Phosphorylation of MAPK pathway by LDL
The MAPK signal transduction pathway represents an
important mechanism by which growth factors regulate
cell proliferation. In mammalian cells the MAPK fam-
ily include the extracellular signal-regulated kinases 1
and 2 (Erk 1/2), or p42, and p44mapk, the JNK/or stress-
activated protein kinase (SAPK) and p38mapk. We have
previously reported that LDL can active the p42/p44mapk
in mesangial cells [22]. To further explore if LDL will acti-
vate other members of the MAPK family, mesangial cells
were treated with LDL (50 lg/mL) for 5 minutes. Cytoso-
lic proteins were analyzed by SDS-PAGE, transferred
to nitrocellulose membranes, and immunoblotted with
either antiphospho-p42/p44mapk antibodies (1:4000 dilu-
tion), or antiphospho-p38mapk (1:1000 dilution), and/or
antiphospho-JNK antibodies (1:1000 dilution). The im-
munoreactive bands were visualized using enhanced
chemiluminescence (ECL) reagent. The membranes
were also immunoblotted with total nonphosphorylated
p42/p44mapk, p38mapk, and JNK antibodies to ensure equal
amounts of MAPK loaded into the gels.
The results shown in Figure 6 demonstrate that LDL
resulted in a significant increase in the phosphorylation
of p42/p44mapk (P < 0.02) (N = 12), p38mapk (P < 0.02)
(N = 12), and of JNK (P < 0.001) (N = 12). Total non-
phosphorylated p42/p44mapk, p38mapk, and JNK were not
different between control and LDL-treated cells.
Role of JNK in LDL-induced TGF-b production
To explore whether the MAPK pathway modulates
the production of TGF-b in response to LDL, we mea-
sured TGF-b protein levels in mesangial cells treated with
LDL (50 lg/mL) for 24 hours, in the presence and ab-
sence of membrane permeable inhibitors of p42/p44mapk
(PD98059), 40 lmol/L, p38mapk (SB 203580), 10 lmol/L,
and JNK (SP600125), 30 lmol/L. The results shown in
Figure 7 demonstrate that LDL once again produced a
significant increase in TGF-b protein levels compared
to unstimulated cells. This increase in TGF-b protein
levels was significantly reduced by the JNK inhibitor
SP600125 (155.6 ± 21.7 pg/mL vs. 54.7 ± 6.9 pg/mL LDL
vs. LDL+SP600125) (P < 0.0001) (N = 10). Treatment of
mesangial cells with the JNK inhibitor SP600125 signif-
icantly reduced the basal production of TGF-b protein
levels (29.3 ± 3.0 pg/mL vs. 84.1 ± 14.6 pg/mL; SP600125
vs. C) (P < 0.001) (N = 10). On the other hand, selective
inhibition of p42/p44mapk by PD98059 and of p38mapk by
SB203580 did not significantly alter the increased produc-
tion of TGF-b protein levels in response to LDL stimu-
lation, nor did they significantly influence the basal levels
of TGF-b . These findings demonstrate that LDL utilizes
the JNK pathway to modulate the production of TGF-b
in mesangial cells.
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Fig. 7. Role of c-Jun NH2-terminal kinase (JNK) in low-density lipoprotein (LDL)-induced transforming growth factor-b (TGF-b) production.
Quiescent mesangial cells were stimulated with LDL (50 lg/mL) for 24 hours in presence or absence of p44/42mapk inhibitor, PD98059 (40 lmol/L)
(A), p38mapk inhibitor, SB203580 (10 lmol/L) (B), and JNK inhibitor, SP600125 (30 lmol/L) (C). Conditioned media were collected and activated
to determine the total level of TGF-b1 protein using colorimetric enzyme-linked immunosorbent assay (ELISA) kit assay. Values are means ± SE
of TGF-b1 levels expressed in pg/mL. ∗P < 0.05 vs. control; #P < 0.0001 vs. LDL (N = 4 to 10 experiments).
Role of MAPK in LDL-induced CTGF production
To explore whether the MAPK pathway modulates
the production of CTGF in response to LDL, we mea-
sured CTGF protein levels in mesangial cells treated with
LDL (50 lg/mL) for 24 hours, in the presence and ab-
sence of membrane permeable inhibitors of p42/p44mapk
(PD98059), 40 lmol/L, p38mapk (SB 203580), 10 lmol/L,
and JNK (SP600125), 30 lmol/L. CTGF levels were mea-
sured by Western blots. The results shown in the Figure 8
demonstrate that LDL once again produced a significant
increase in CTGF protein levels compared to unstimu-
lated cells. However, in the presence of the p44/42mapk
inhibitor PD 98059 and/or the JNK inhibitor SP600125,
the increase in CTGF protein levels in response to LDL
was significantly suppressed (P < 0.005) (N = 8). On the
other hand, inhibition of the p38mapk by SB203580 did not
alter the expression of CTGF in response to LDL. Actin
protein levels measured at the same time and in the same
cell extracts were not significantly different among the
groups.
This is the first demonstration that the induction of
CTGF by LDL is mediated via phosphorylation of the
MAPK pathway.
LDL increases collagen I via JNK-dependent pathway
To evaluate whether activation of the MAPK pathway
modulates the increase in collagen I in response to LDL,
mesangial cells were pretreated with the p42/p44mapk
(PD98059), 40 lmol/L, p38mapk (SB 203580), 10 lmol/L,
and JNK (SP600125), 30lmol/L inhibitors for 45 minutes,
followed by LDL stimulation for 24 hours. The results
shown in Figure 9 demonstrate that LDL once again pro-
duced a significant increase in collagen I protein levels
compared to unstimulated cells. This increase in collagen
I protein levels was significantly reduced by the JNK in-
hibitor SP600125 (P < 0.001) (N = 8). However, selective
inhibition of p42/p44mapk by PD98059 and of p38mapk by
SB203580 did not significantly alter the increased pro-
duction of collagen I protein levels in response to LDL
stimulation. These findings demonstrate that LDL uti-
lizes the JNK pathway to modulate the production of
collagen I in mesangial cells. Actin protein levels mea-
sured at the same time and in the same cell extracts were
not significantly different among the groups.
DISCUSSION
In the present study we have demonstrated that LDL
exerts a significant effect on the expression of CTGF and
collagen I in mesangial cells. We have shown that LDL
increases the protein levels of CTGF, TGF-b , and colla-
gen I in mesangial cells. This effect of LDL was mediated
via phosphorylation of the MAPK pathway.
Poorly controlled type 1 diabetes is usually associated
with elevated levels of plasma LDL, intermediate den-
sity lipoproteins, and very low-density lipoprotein lev-
els [11–14]. In contrast, HDL cholesterol levels are low
during poor glycemic control and increase to normal or
above normal when adequate control is attained [24, 25].
In the Pittsburgh Epidemiology of Diabetes Complica-
tions Cohort of type 1 diabetic patients, Orchard et al [26]
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Fig. 8. Effect of mitogen-activated protein kinase (MAPK) inhibitors on low-density lipoprotein (LDL)-induced regulation of connective tissue
growth factor (CTGF). (A) Mesangial cells were stimulated with LDL (50 lg/mL) for 24 hours in presence or absence of p44/42mapk inhibitor,
PD98059 (40 lmol/L) for 45minutes. Equal amounts of proteins were resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) (12%) and immunoblotted with an antibody against CTGF (1:1000) and actin (1:1000). Bar graph represents intensities of CTGF bands
relative to actin expressed as percent above control. Blots shown are representative of eight experiments. ∗P < 0.05 vs. control; #P < 0.005 vs. LDL.
(B) Quiescent mesangial cells were stimulated by LDL (50 lg/mL) for 24 hours in presence or absence of p38mapk inhibitor, SB203580 (10 lmol/L)
for 45minutes. Blots shown are representative of four experiments. ∗P < 0.05 vs. control. (C) Quiescent mesangial cells were stimulated by LDL
(50 lg/mL) for 24 hours in presence or absence of c-Jun NH2-terminal kinase (JNK) inhibitor, SP600125 (30 lmol/L) for 45minutes. Blots shown
are representative of eight experiments. ∗P < 0.05 vs. control; #P < 0.001 vs. LDL.
related baseline lipids to nephropathy and showed that
LDL cholesterol and triglycerides and hypertension were
predictive of nephropathy onset within 5 years but not 6
to 10 years. Hemoglobin A1c (HbA1c) levels predicted
the later onset of nephropathy [26]. Abnormalities in the
distribution of lipoprotein subclasses in type 1 diabetes
have been recently described [27]. Using nuclear mag-
netic resonance (NMR), LDL particle concentration was
positively associated with albumin excretion rate (AER)
and LDL diameter was inversely associated with AER
[27]. Interestingly, a recent study showed that the regres-
sion of microalbuminuria in type 1 diabetic patients is
associated with low levels of total serum cholesterol and
triglycerides [28]. Furthermore, type 1 diabetic patients
with proteinuria have a tenfold risk of macrovascular dis-
ease relative to type 1 patients without proteinuria. The
relation of microalbuminuria to vascular disease compli-
cations such as carotid intima-medial thickness was re-
cently illustrated in the DCCT/EDIC cohort of type 1
diabetic patients [29]. Diabetic renal disease is associ-
ated with elevations of blood pressure and dyslipidemia,
conditions that predict and accelerate the progression of
vascular disease in diabetic patients [28].
Although hyperlipidemia is now considered a risk fac-
tor for the progression of renal damage, the initiating and
sustaining signals that link hyperlipidemia to glomeru-
lar sclerosis are not fully realized. Accumulation of LDL
within the mesangium may activate glomerular cells to
produce various cytokines and growth factors that may al-
ter mesangial cell behavior by inducing cell proliferation,
hypertrophy and increasing ECM accumulation [19, 20].
In this regard our findings demonstrate that the protein
levels of TGF-b , CTGF and collagen I were induced in
mesangial cells in response to LDL challenge. Inhibition
of TGF-b activity with neutralizing antibodies prevented
the rise in CTGF and collagen I, thus demonstrating that
the increase in CTGF and collagen I protein levels in re-
sponse to LDL were mediated via autocrine activation
of TGF-b . These data support other findings and lends
support to the notion that CTGF and collagen I is down-
stream targets of TGF-b .
Even though TGF-b has long been regarded as a ma-
jor driving force in many progressive fibrotic diseases,
attention has recently focused on the role of CTGF as a
profibrotic factor [30]. CTGF, a newly described factor
that promotes ECM deposition and fibrosis in many tis-
sue, appears to act downstream of TGF-b to induce ECM
production [31]. Several studies demonstrated CTGF is
an important mediator in the pathogenesis of glomeru-
losclerosis in diabetic nephropathy and other forms of
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Fig. 9. Role of mitogen-activated protein kinase (MAPK) pathway in low-density lipoprotein (LDL)-induced collagen I expression. (A) Quiescent
mesangial cells were stimulated with LDL (50 lg/mL) for 24 hours in presence or absence of p44/42mapk inhibitor, PD98059 (40 lmol/L) for 45minutes.
Equal amounts of proteins were resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (12%) and immunoblotted
with an antibody against collagen I (1:1000) and actin (1:1000). Bar graph represents intensities of collagen I bands relative to actin expressed as
percentage above control. Blots shown are representative of seven experiments. ∗P < 0.05 vs. control. (B) Quiescent mesangial cells were stimulated
by LDL (50 lg/mL) for 24 hours in presence or absence of p38mapk inhibitor, SB203580 (10 lmol/L) for 45minutes. Blots shown are representative
of four experiments. ∗ P < 0.05 vs. control. (C) Quiescent mesangial cells were stimulated by LDL (50 lg/mL) for 24 hours in presence or absence
of c-Jun NH2-terminal kinase (JNK) inhibitor, SP600125 (30 lmol/L) for 45minutes. Blots shown are representative of eight experiments. ∗P < 0.05
vs. control; #P < 0.0001 vs. LDL.
renal disease [32–35]. CTGF in mesangial cells is up-
regulated by high extracellular glucose, TGF-b and an-
giotensin II and is down-regulated by nitric oxide [31, 36–
38]. However, in the present study we demonstrate for the
first time that LDL can up-regulate CTGF in mesangial
cells.
It is widely accepted that LDL stimulation results in
the activation of members of the MAPK family, and ac-
tivation of this pathway is known to be important in reg-
ulating gene expression and mesangial cell growth and
function [22, 39]. The MAPK are a family of serine-
threonine protein kinases that are activated in response
to a variety of extracellular stimuli. ERK (p42/44mapk),
p38mapk, and JNK constitute three major subfamilies of
MAPK that appear to mediate cellular responses, in-
cluding proliferation, differentiation, and apoptosis [40].
ERK plays a major role in cell proliferation and differen-
tiation, as well as in survival mediated by various growth
factors [40]. On the other hand, p38mapk and JNK are
activated by various inflammatory cytokines and environ-
mental stressors and they play important roles in apop-
tosis and cytokine production [41]. To elucidate which
member of the MAPK family may be responsible for
the LDL-induced increase in CTGF and collagen I, we
elected to study the role of p42/44mapk, p38mapk, and JNK
in mesangial cells. Our findings indicate that inhibition of
JNK by SP600125 suppressed the expression of TGF-b ,
CTGF, and collagen I levels in response to LDL stimula-
tion, whereas inhibition of the p42/44mapk by PD98059
resulted in suppression of LDL-induced expression of
CTGF. On the other hand, blockade of the p38mapk path-
way by SB203580 did not significantly alter the expression
of TGF-b , CTGF, or collagen I in response to LDL. This
finding implicates JNK as a key player in modulating the
signals through which LDL promotes TGF-b , CTGF, and
collagen I expression in mesangial cells. Furthermore, it
is of interest to note that inhibition of basal JNK activity
also reduced the basal production of TGF-b , thus impli-
cating a key role for JNK kinase in modulating the pro-
duction of TGF-b in mesangial cells. Other studies have
implicated JNK in TGF-b1–induced CTGF mRNA ex-
pression in human lung fibroblasts, whereas p38mapk and
p42/44mapk pathways were implicated in TGF-b–induced
ECM deposition [42–44].
Although the initiating and sustaining signals that link
LDL to CTGF expression are not yet fully defined, sev-
eral possibilities may exist. Our data demonstrate that
LDL stimulates JNK activation and JNK has been shown
to bind and phosphorylate the DNA binding protein c-
Jun and increase its transcriptional activity [41]. c-Jun is a
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component of the activating protein-1 (AP-1) transcrip-
tion complex which is an important regulator of gene ex-
pression [45]. In this regard, the autoinduction of TGF-b
has been shown to be mediated via activation of the AP-1
complex [46]. Once activated, TGF-b can induce CTGF
expression via the SMAD pathway [47]. In fact, a SMAD
response element is present on the promoter of the CTGF
gene [48].
CONCLUSION
We demonstrate that the expression of CTGF and col-
lagen I in mesangial cells are up-regulated by LDL and
that this regulation is mediated via autocrine activation
of TGF-b . The results also implicate JNK as a key player
in modulating the expression of TGF-b , CTGF, and colla-
gen I in response to LDL stimulation. The data also point
to a potential novel mechanistic pathway through which
lipoproteins may promote diabetic glomerular injury.
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